Skip to main content
. 2023 Jun 12;82(9):1130–1141. doi: 10.1136/ard-2023-223916

Figure 2.

Figure 2

Exposure-adjusted incidence of adjudicated MACE in higher CV risk populations by age. MACE defined as CV death (includes acute myocardial infarction, sudden cardiac death, heart failure, CV procedure-related death, death due to CV haemorrhage, fatal stroke, pulmonary embolism and other CV causes), non-fatal myocardial infarction and non-fatal stroke. ADA, adalimumab; csDMARD, conventional synthetic disease-modifying antirheumatic drug; CV, cardiovascular; EAIR, exposure-adjusted incidence rate; EOW, every other week; MACE, major adverse cardiovascular event; MTX, methotrexate; PY, patient-years; QD, once daily; UPA, upadacitinib.